Inhibitory effect of metastasis by combined administration with interleukin-2 and sizofiran, a single glucan - immunohistochemical study

Biotherapy

Volumn 9, Issue 4, 1996, Pages 263-269

  Kano, Yuji ^a,b   Kakuta, Hiroyuki ^a   Hashimoto, Junichi ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EL 4 lymphoma; HE stain; Immunohistochemical study; Recombinant human interleukin 2 (rIL 2); Sizofuran (SPG)

Indexed keywords

GANGLIOTETRAOSYLCERAMIDE; GLUCAN; IMUNACE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT INTERLEUKIN 2; SCHIZOPHYLLAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; DRUG POTENTIATION; EFFECTOR CELL; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPHOMA; METASTASIS; MOUSE; NONHUMAN; PERITONEUM CELL; PRIORITY JOURNAL; SPLEEN; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0030465291     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02620740     Document Type: Article

References (16)

1. Kano Y, Kakuta H, Hashimoto J. Augmentation of antitumor effect by combination therapy of interleukin-2 and sizofiran on intraperitoneally implanted EL-4 lymphoma. Biotherapy 1996. In press.
2. Chen JT, Hasumi K. Activation of peritoneal macrophages in patients with gynecological malignancies by sizofiran and recombinant interferon-gamma. Biotherapy 1993; 6: 189-94.
3. Fume H. Biological characteristics and clinical effect of sizofilan (SPG). Drugs of Today 1987; 23: 335-46.
4. Ghose T, Guclu A, Tai J, Mammen M, Norvell ST. Immunoprophylaxis and immunotherapy of EL-4 lymphoma. Europ. J. Cancer 1977; 13: 925-935.
5. Ota T, Tanino M, Kohno H, Funamoto H, Odashima S. Isolation and characterization of a low metastatic variant from EL-4 mouse T-lymphoma. Clin. Exp. Metastasis 1992; 10: 297-308.
6. Shimokawara l, Imamura M, Yamanaka N, et al. Identification of lymphocyte subpopulations in human breast cancer tissue and its significance. Cancer 1982; 49: 1456-64.
7. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin 2- activated autologous human peripheral blood lymphocyte. J Exp Med 1982; 155: 1823-41.
8. Sugawara I, Lee KC, Wong M. Schizophyllan(SPG)-treated macrophages and anti-tumor activities against syngeneic and allogeneic tumor cells: I. Characteristics of SPG-treated macrophages. Cancer Immunol Immunother 1984; 16: 137-44.
9. Tsuchiya Y, Igarashi M, Inoue M, Kumagai K. Cytokine-related immunomodulating activities of an anti-tumor glucan, sizofiran (SPG). J Pharmacobio-Dyn 1989; 12: 616-25.
10. Shimizu Y, Hasumi K, Masubuchi K. Augmenting effect of Sizofiran, on the immunofunction of regional lymph nodes in cervical cancer. Cancer 1992; 69:1188-94.
11. Tsuchiya Y, Yamamoto M, Igarashi M, Suzuki R, Kumagai K. Study on immunomodulating activity of an antitumor glucan, sizofiran at tumoral factor level. Clin Immunol 1986; 18: 575-84.
12. Wolf GT, Hudson JL, Paterson KA. Lymphocyte subpopulations infiltration squamous carcinomas of the head and neck: Correlations with extent of tumor and prognosis. Otolaryngol. Head and Neck Surg. 1986; 95: 142-52.
13. Horst HA, Horny HP. Characterization and frequency distribution of lymphoreticular infiltrates in axillary lymph node metastases of invasive ductacarcinoma of the breast. Cancer 1987; 60: 3001-7.
14. Rabin BS, Johnson J, Ciaassen D. Identification of subsets of lymphocytes infiltration head and neck tumor tissue: A preliminary report. Laryngoscope 1984; 94: 688-90.
15. Eccles SA, Alexander P. Macrophage content of tumors in relation to metastatic spread and host immune reaction. Nature, Lond. 1974; 250: 667-69.
16. Hanna N, Burton R. Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastasis in vivo. Immunology 1981; 127:1754-58.